Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients

Winczura, Piotr; Sosińska-Mielcarek, Katarzyna; Duchnowska, Renata; Badzio, A.; Lakomy, Joanna; Majewska, Hanna; Pęksa, Rafał; Pieczyńska, Beata; Radecka, Barbara; Dębska-Szmich, Sylwia; Adamowicz, Krzysztof; Biernat, Wojciech; Jassem, Jacek

doi:10.1007/s12253-015-9957-0

Cited by 7 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer commonly metastasize to the bone and the hormonal receptor status can predict the metastatic site (3). Most of the patients in the study was in between 50-60 years and least patient was in age between 30-40 years and 70-80 years which was consistent with study conducted by Neesa et al (2018).…”

Section: Discussionsupporting

confidence: 89%

Influence of Age, Estrogen receptor (ER),Progesterone receptor (PR) and Epidermal growth factor -2 (HER-2) in Breast Carcinoma Patient in correlation with Radionuclide Bone Scan – Single Institute Based Experience

Sharmin

Yasmin

Ghosh

et al. 2021

Bangladesh J. Nuclear Med.

View full text Add to dashboard Cite

Background: Breast carcinoma is a common type of malignancy in women worldwide. Radionuclide bone scintigraphy is recognized choice of investigation for the detection of bone metastases both in asymptomatic and symptomatic patients. Biomarkers like Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal growth factor -2 (HER-2) also play important role in the management and prognosis of breast cancer. The study was aimed to find out the relationship between the MDP bone scan findingsand hormone receptor and HER-2 status of breast carcinoma patients referred to the Institute of Nuclear Medicine and Allied Sciences (INMAS), Mitford, Dhaka. Patients and Methods: This cross sectional study was conducted among 301 breast carcinoma patients between January 2018 and December 2019. Planar bone scan and SPECT (if needed) was done to all the patients after intravenous injection of 99mTc-MDP. Receptor status (ER, PR and HER-2) were documented from the patient’s medical records. Breast tumors were classified as (a) Triple positive- HER2-, ER-, and PR-positive) (b) Triple negative- HER2-, ER-, and PR-negative (c) Hormonereceptor (HR) positive (ER+/PR+) with HER-2 negative and d) HR negative (ER-/PR-) with HER-2 positive.Patients were broadly grouped according to age as A. less than 50 years (n = 59) and B. more than 50 (n = 260 ) years. Results: The mean age of the patients enrolled for this study was 59.02±9.3 with range of 32 to 81 years. Out of the 301 patients, positive bone scans were found in 105 (34.8%) and negative bone scan were found 196 (66.2%). Patients of group A (<50years) with triple negative and HR+/HER-status had no bone or bone with visceral metastases. Triple positive subtype had 2 bone metastases, and HR-/HER-2+ subtype had 2 bone metastases and 1 had bone with visceral metastases. Group B (> 50years) patients having HR+/HER2- receptor status showed 16% solitary metastases, 53.2% multiple metastases, 33.3% extensive bony metastases, 13.6% bone with visceral metastases. Triple negative subtype showed 36.0 % solitary metastases, 19.1% bone with visceral metastases. Triple positive subtype group had 40.0% solitary metastases, 34.0 % multiple metastases, 66.7% extensive bony metastases, and 13.6% bone with visceral metastases. HR-/HER-2+ subtype group had 8% solitary metastases, 12.8% multiple metastases, and 18.2 % bone metastases with visceral involvement Overall relationship between bone scan and hormone receptor subtype, showed that most of the patients had HR+/ HER-2-(35.2%) subtype and 25.6% patient had triple positive, 23.3% patient had triple negative and 15.9% patient had HR-/HER-2 – receptor subtype. This study showed the visceral involvement with bone metastases (13 % in HR+/HER-2- 52.2 % in triple negative, 13 % in triple positive, 21.7 % in HR-/HER-2+subtype). Highest bone only metastases (35) in triple positive and HR+/HER-2-(31) subtype. Most of the patiens who had bone metastases with visceral involvement belong to triple negative (52.2%) and HER-2 subtypes -HR-/HER-2+ (21.7%). The result was significant (P<0.001). Conclusion: It is observed from this study that triple positive and HR+/HER-2- were more likely to develop bone metastases than triple negative and HR-/HER-2-. Patients with bone scan negative and HR-/HER-2- or triple negative receptor status most likely develop visceral metastases Bangladesh J. Nuclear Med. 22(2): 114-118, Jul 2019

show abstract

Section: Discussionsupporting

confidence: 89%

Influence of Age, Estrogen receptor (ER),Progesterone receptor (PR) and Epidermal growth factor -2 (HER-2) in Breast Carcinoma Patient in correlation with Radionuclide Bone Scan – Single Institute Based Experience

Sharmin

Yasmin

Ghosh

et al. 2021

Bangladesh J. Nuclear Med.

View full text Add to dashboard Cite

show abstract

“…A more recent study aimed to relate the immunohistochemical expression of specific proteins in primary tumours with the development of BM [ 86 ]. For this purpose a total of 184 patients were analysed (n = 113 with BM and n = 71 with extraskeletal metastases) for ER, PR, HER2, Ki67, and six exploratory proteins: COX2, CK5/6, CXCR4, PTHR1, OPN, and CaSR.…”

Section: Risk Factors For Bone Metastasesmentioning

confidence: 99%

“…PTHR1 overexpression was found in 34% of patients with BM compared to 16% without BM (p = 0.007). While there seemed to be a positive relationship between PTHR1 overexpression and BM in the univariate analysis, this did not hold true in the multivariate model where only ER and absence of cytoplasmic OPN were independent risk factors for BM (p = 0.002 and p = 0.018) [ 86 ].…”

Section: Risk Factors For Bone Metastasesmentioning

confidence: 99%

Bone metastasis risk factors in breast cancer

Pulido¹,

Vendrell²,

Ferreira³

et al. 2017

ecancer

View full text Add to dashboard Cite

Bone is the single most frequent site for bone metastasis in breast cancer patients. Patients with bone-only metastasis have a fairly good prognosis when compared with patients with visceral disease. Nevertheless, cancer-induced bone disease carries an important risk of developing skeletal related events that impact quality of life (QoL). It is therefore particularly important to stratify patients according to their risk of developing bone metastasis. In this context, several risk factors have been studied, including demographic, clinicopathological, genetic, and metabolic factors. Most of them show conflicting or non-definitive associations and are not validated for clinical use. Nonetheless, tumour intrinsic subtype is widely accepted as a major risk factor for bone metastasis development and luminal breast cancer carries an increased risk for bone disease. Other factors such as gene signatures, expression of specific cytokines (such as bone sialoprotein and bone morphogenetic protein 7) or components of the extracellular matrix (like bone crosslinked C-telopeptide) might also influence the development of bone metastasis. Knowledge of risk factors related with bone disease is of paramount importance as it might be a prediction tool for triggering the use of targeted agents and allow for better patient selection for future clinical trials.

show abstract

“…Alongside this molecular knowledge, multiple bone metastasis-specific biomarkers have been proposed. For example, Winczura et al ( 2015 ) have found that a reduction of osteopontin was consistently observed in patients who developed bone metastasis, whereas Mihai et al ( 2006 ) have found that the calcium-sensing receptor (CaR) was commonly expressed in breast tumours, which metastasised to the bone. Although our models uncovered some proteins previously known to be associated with metastasis, it also uncovered several proteins that generally have not been studied in the context of BC tropism to specific metastatic sites/tissues, or have not been implicated directly in regulating metastasis.…”

Section: Discussionmentioning

confidence: 99%

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers

et al. 2017

View full text Add to dashboard Cite

Background:Although distant metastasis (DM) in breast cancer (BC) is the most lethal form of recurrence and the most common underlying cause of cancer related deaths, the outcome following the development of DM is related to the site of metastasis. Triple negative BC (TNBC) is an aggressive form of BC characterised by early recurrences and high mortality. Athough multiple variables can be used to predict the risk of metastasis, few markers can predict the specific site of metastasis. This study aimed at identifying a biomarker signature to predict particular sites of DM in TNBC.Methods:A clinically annotated series of 322 TNBC were immunohistochemically stained with 133 biomarkers relevant to BC, to develop multibiomarker models for predicting metastasis to the bone, liver, lung and brain. Patients who experienced metastasis to each site were compared with those who did not, by gradually filtering the biomarker set via a two-tailed t-test and Cox univariate analyses. Biomarker combinations were finally ranked based on statistical significance, and evaluated in multivariable analyses.Results:Our final models were able to stratify TNBC patients into high risk groups that showed over 5, 6, 7 and 8 times higher risk of developing metastasis to the bone, liver, lung and brain, respectively, than low-risk subgroups. These models for predicting site-specific metastasis retained significance following adjustment for tumour size, patient age and chemotherapy status.Conclusions:Our novel IHC-based biomarkers signatures, when assessed in primary TNBC tumours, enable prediction of specific sites of metastasis, and potentially unravel biomarkers previously unknown in site tropism.

show abstract

Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients

Cited by 7 publications

References 33 publications

Influence of Age, Estrogen receptor (ER),Progesterone receptor (PR) and Epidermal growth factor -2 (HER-2) in Breast Carcinoma Patient in correlation with Radionuclide Bone Scan – Single Institute Based Experience

Influence of Age, Estrogen receptor (ER),Progesterone receptor (PR) and Epidermal growth factor -2 (HER-2) in Breast Carcinoma Patient in correlation with Radionuclide Bone Scan – Single Institute Based Experience

Bone metastasis risk factors in breast cancer

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers

Contact Info

Product

Resources

About